AMR vs Papua New Guinea: Hepatitis B surface antigen (HBsAg) prevalence
AMR
0.0%
in 2024
Papua New Guinea
2.5%
in 2024
AMR rank
12th
Papua New Guinea rank
10th
Hepatitis B surface antigen (HBsAg) prevalence over time
- AMR
- Papua New Guinea
How they compare
Papua New Guinea currently reports 2.5% against 0.0% in AMR, a difference of 2.5%.
Across all 10 years both countries report, Papua New Guinea has been ahead every year.
AMR ranks 12th and Papua New Guinea ranks 10th of 13 groups.
Papua New Guinea has averaged higher in every one of the 2 decades both report.
Head to head by decade
| Decade | AMR | Papua New Guinea | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 0.0% | 2.0% | 1.9% | Papua New Guinea |
| 2020s | 0.0% | 2.4% | 2.4% | Papua New Guinea |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher hepatitis b surface antigen (hbsag) prevalence, AMR or Papua New Guinea?
- Papua New Guinea, at 2.5% against 0.0% in AMR as of 2024.
- What is the difference in hepatitis b surface antigen (hbsag) prevalence between AMR and Papua New Guinea?
- 2.5%, with Papua New Guinea ahead.
- How many years of comparable data are there for AMR and Papua New Guinea?
- 10 years are reported by both, from 2015 to 2024.
- How do AMR and Papua New Guinea rank globally for hepatitis b surface antigen (hbsag) prevalence?
- AMR ranks 12th and Papua New Guinea ranks 10th of 13 groups.
- Where does this data come from?
- World Health Organization, Global Health Observatory, published as Hepatitis B surface antigen (HBsAg) prevalence (%). Statizoid refreshes it automatically from the source and publishes the full history for both places.